Abstract
Glioma is a type of aggressive and incurable brain tumor. Patients with glioma are highly resistant to all types of therapies, including immunotherapies. Epigenetic reprogramming is a key molecular hallmark in tumors across cancer types, including glioma. Mounting evidence highlights a pivotal role of epigenetic regulation in shaping tumor biology and therapeutic responses through mechanisms involving both glioma cells and immune cells, as well as their symbiotic interactions in the tumor microenvironment (TME). In this review, we discuss the molecular mechanisms of epigenetic regulation that impacts glioma cell biology and tumor immunity in both a cell-autonomous and non-cell-autonomous manner. Moreover, we provide an overview of potential therapeutic approaches that can disrupt epigenetic-regulated tumor-immune symbiosis in the glioma TME.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 429-442 |
| Number of pages | 14 |
| Journal | Trends in Molecular Medicine |
| Volume | 30 |
| Issue number | 5 |
| DOIs | |
| State | Published - May 2024 |
Funding
This work was supported in part by National Institutes of Health (NIH) R01 NS124594 (P.C.), NIH R01 NS127824 (P.C.), and Department of Defense (DoD) Career Development Award W81XWH-21-1-0380 (P.C.).
Keywords
- epigenetics
- glioma
- immunotherapy
- therapeutic potential
- tumor-immune symbiosis
ASJC Scopus subject areas
- Molecular Medicine
- Molecular Biology
